个人简介：
夏琳，2010-2015年博士就读于厦门大学生命科学学院，并于2016-2018年厦门大学公共卫生学院以及德克萨斯州立大学休斯顿健康科学中心进行博士后研究，现任药学院刘文课题组助理教授。主要从事肿瘤免疫治疗靶点的开发、机制及其治疗策略研究，并结合表观遗传学探索肿瘤发生发展的分子机制，以增强肿瘤的免疫治疗效果。
研究方向：
1、表观遗传调控因子在肿瘤免疫治疗中的功能及分子机制研究；
代表性论文：
1、Lin Xia#，Lun-zhi Yuan#, Ya-hong Hu#, Jun-yi Liu#, Guo-sheng Hu#, Ruo-yao Qi, Tian-ying Zhang, Hua-long Xiong, Zao-zao Zheng, Hong-wei Lin, Jia-mo Zhang, Chao Yu, Ming Zhou, Jian Ma, Tong Cheng, Ri-rong Chen, Yi Guan, Ning-shao Xia* and Wen Liu*. A SARS-CoV-2-specific CAR-T-cell model identifies felodipine, fasudil, imatinib, and caspofungin as potential treatments for lethal COVID-19. Cell Mol Immunol. 2023 Apr;20(4):351-364.
2、Zao-zao Zheng#, Lin Xia#, Guo-sheng Hu#, Jun-yi Liu, Ya-hong Hu, Yu-jie Chen, Jia-yin Peng, Wen-juan Zhang*, and Wen Liu* Super-enhancer-controlled positive feedback loop BRD4/ERα-RET-ERα promotes ERα-positive breast cancer. Nucleic Acids Res. 2022 Oct 14;50(18):10230-10248.
3、Xia L#, Liu JY#, Zheng ZZ#, Chen YJ#, Ding JC#, Hu YH, Hu GS, Xia NS, Liu W*. BRD4 inhibition boosts the therapeutic effects of epidermal growth factor receptor-targeted chimeric antigen receptor T cells in glioblastoma. Mol Ther. 2021 Oct 6;29(10):3011-3026.
4、Xia L#, Zheng Z#, Liu JY#, Chen YJ#, Ding J#, Hu GS, Hu YH, Liu S, Luo WX, Xia NS, Liu W*. Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition. Cancer Immunol Res. 2021 Jun;9(6):707-722.
5、Xia L#, Zheng ZZ#, Liu JY#, Chen YJ#, Ding JC#, Xia NS, Luo WX*, Liu W*. EGFR-targeted CAR-T cells are potent and specific in suppressing triple-negative breast cancer both in vitro and in vivo. Clin Transl Immunology. 2020 May 3;9(5):e01135.
6、Zhou B#, Xia L#, Zhang T, You M, Huang Y, He M, Su R, Tang J, Zhang J, Li S, An Z, Yuan Q, Luo W*, Xia N*. Structure guided maturation of a novel humanized anti-HBV antibody and its preclinical development. Antiviral Res. 2020 Aug;180:104757.
7、Lin Xia#，Ruopeng Su#，Zhiqiang An，Tong-Ming Fu & Wenxin Luo*，Human cytomegalovirus vaccine development: Immune responses to look into vaccine strategy.，Human Vaccines & Immunotherapeutics，2018，14（2）：292-303.
8、Ciming Kang#，Lin Xia#，Yuanzhi Chen，Tianying Zhang，Yiwen Wang，Bing Zhou，Min You，Quan Yuan，Chi-Meng Tzeng，Zhiqiang An，Wenxin Luo*，Ningshao Xia，A novel therapeutic anti-HBV antibody with increased binding to human FcRn improves in vivo PK in mice and monkeys.，Protein & Cell，2018，9（1）：130-134.
9、Xia, Lin#，Xian, Yangfei#，Wang, Daning，Chen, Yuanzhi，Huang, Xiaofen，Bi, Xingjian，Yu, Hai，Fu, Zheng，Liu, Xinlin，Li, Shaowei，An, Zhiqiang，Luo, Wenxin*，Zhao, Qinjian*，Xia, Ningshao，A human monoclonal antibody against HPV16 recognizes an immunodominant and neutralizing epitope partially overlapping with that of H16.V5.，Sci Rep，2016，6：19042-19042.
10、Xia, Lin#，Zhang, Juan#，Cui, Chuanjia，Bi, Xingjian，Xiong, Junhui，Yu, Hai，An, Zhiqiang，Luo, Wenxin*，Xia, Ningshao，In vitro affinity maturation and characterization of anti-P24 antibody for HIV diagnostic assay.，J Biochem，2015，158（6）：531-538.
11、Freed, Daniel C(#)，Tang, Qi，Tang, Aimin，Li, Fengsheng，He, Xi，Huang, Zhao，Meng, Weixu，Xia, Lin，Finnefrock, Adam C，Durr, Eberhard，Espeseth, Amy S，Casimiro, Danilo R，Zhang, Ningyan，Shiver, John W，Wang, Dai，An, Zhiqiang，Fu, Tong-Ming，Pentameric complex of viral glycoprotein H is the primary target for potent neutralization by a human cytomegalovirus vaccine.，Proc Natl Acad Sci U S A，2013，110（51）：E4997-E5005.
12、Zheng Qingbing#; Xia Lin#; Wu Wai Lan; Zheng Zhenhua; Huo Yongting; Wu Jun; Liu Yanning; Yu Hai; Chen Yixin; Lau Siu Ying; Chen Honglin*; Luo Wenxin*; Xia Ningshao, Properties and Therapeutic Efficacy of Broadly Reactive Chimeric and Humanized H5-Specific Monoclonal Antibodies against H5N1 Influenza Viruses, Antimicrobial Agents and Chemotherapy, 2011, 55(4): 1349~1357.
